The global paradigm for health care innovation has fundamentally changed. At the turn of the millennium, large pharma companies were the hub for traditional research and development initiatives. Fast-forward 20 years and biotech now is leading this charge with fast-paced innovation – and the associated development risk – to provide the next generation of medicines.

The competition is fierce, speeding up time to market for life-changing therapeutics for patients worldwide. To keep pace with this marked shift to biotech drug development activity, clinical research organizations have created new models and resources to help biotech meet the global demand for innovative new options for patients, such as cell and gene therapies and other technologies.

Outsourced innovation and the birth of biotech

As a result of the millennium R&D crisis – which increased clinical development timelines, competition and associated costs to bring a new medication to the market – pharmaceutical companies had to rethink their R&D strategies. The pharmaceutical industry is resource intensive and characterized by a fierce competition in time to market. The necessity to maintain its profit margin over time despite the increasing costs of drug development led to the birth and growth of a flourishing outsourcing market.

However, even after the initial resizing of its clinical development, the pharmaceutical industry had yet to cope with its R&D, looking for alternative models to increase efficiency, speed and efficacy. 

Some of the key advantages are clear. For example, making performance-based investments to de-risk failure. But with time and under the right blend of investments, innovation and market opportunities (luck!), “contract R&Ds” can turn into a successful new biotech company.

Figure 1: Birth of a biotech

Biotech now represents a new era for the rapid development of new medicines with new timelines and cost structures. The industry is moving toward more efficient development models and embracing the role of outsourcing to help build infrastructure to be most effective, or to scale when needed.

New models from CROs are enabling further biotech expansion

Demands of a rapidly growing biotech company put stresses on development processes, timelines and workforces. When drug development is globalized, companies must navigate local regulations that can vary significantly by country. This can get particularly complex when hiring local teams, while requiring local expertise and knowledge of requirements.

Contract research organizations (CROs) have long offered a selection of resourcing models to the drug development industry. Large pharma, with an existing global presence, tend to use outsourcing models for containment, i.e., a strategy aimed to reduce resource utilization, rather than one focused on upscaling. Interestingly, for a growing biotech, upscaling models can address the needs of rapid expansion in response to pipeline and company growth. For many biotech, traditional resourcing models such as staffing (too small?) or functional service outsourcing (too large?) might not be the best solution for a growing biotech, so alternative models should be investigated to evolve as the biotech company is growing.

A hybrid model can potentially represent a new, more customized option, where biotech companies can make the best choice depending on the stage of their company’s development. Table 1 describes the features of this new tailored model and its application in biotech companies’ lifecycle management.

Table 1: Hybrid resource model features

Leading health care innovation

To help accelerate the new paradigm for drug development, CROs must keep pace with the resourcing needs of biotech to meet global demand for new therapeutics. This will require new creative ways to combine operational models for biotech to position CROs as global extensions of biotech teams. In the short term, we will see more combinations of different models that form seamless, flexible options designed to evolve with the need of each biotech.
 

Davide Garrisi, who joined PPD in 2016, has held a variety of roles of increasing responsibility in operational and commercial strategy in the CRO industry and has authored a number of articles and white papers on clinical research topics. He holds a degree in pharmaceutical chemistry and technology and an executive MBA.